Yale School of Management - Fuad El-Hibri '82

"What’s unique about Yale SOM is the combined private and public management approach with a strong focus on entrepreneurship and leadership. These, along with a student-teacher ratio that is conducive to optimal learning, provide a solid foundation and broad understanding of business concepts that give students the confidence and wherewithal to succeed. I am proud to be a graduate of Yale SOM."

Fuad El-Hibri is the chief executive officer and chairman of the board of directors of Emergent BioSolutions Inc., a publicly traded biopharmaceutical company focused on developing, manufacturing and commercializing vaccines and antibody therapies to prevent or treat disease. The company’s current marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the FDA for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, flu, and chlamydia.

Mr. El-Hibri served as chairman of Digitel C.A. and president of Digicel de C.V., both privately held telecommunications companies, and chairman and president of East West Resources Corporation, a venture capital and financial consulting firm.

Mr. El-Hibri is chairman of the board of the El-Hibri Charitable Foundation. He is also a member of the board of trustees of the National Health Museum, and a member of the board of directors of the Heifetz International Music Institute and the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University.

Mr. El-Hibri holds a Master’s degree in public and private management from Yale University and a BA in Economics from Stanford University.